Design and synthesis of carbohydrate-based inhibitors of protein-carbohydrate interactions

Current Opinion in Structural Biology

Volumn 6, Issue 5, 1996, Pages 703-709

  Von Itzstein, Mark ^a   Colman, Peter ^b  

^a MONASH UNIVERSITY   (Australia)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CARBOHYDRATE BINDING PROTEIN; SELECTIN;

CARBOHYDRATE METABOLISM; CARBOHYDRATE SYNTHESIS; CHOLERA; COMPLICATION; CRYSTAL STRUCTURE; DIABETES MELLITUS; DRUG DESIGN; HUMAN; INFLAMMATION; INFLUENZA; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030272169     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(96)80038-8     Document Type: Article

References (50)

1. Villeret V, Huang SH, Zhang YP, Lipscomb WN: Structural aspects of the allosteric inhibition of fructose-1,6bisphosphatase by AMP: the binding of both the substrate analogue 2,5-anhydro-o-glucitol 1,6-bisphosphate and catalytic metal ions monitored by X-ray crystallography. Biochemistry 1995, 34:4307-4315.
2. Villeret V, Huang SH, Zhang YP, Lipscomb WN: Crystal structure of spinach chloroplast fructose-1,6-biphosphatase at 2.8 angstrom resolution. Biochemistry 1995, 34:4299-4306.
3. Wilson DK, Bohren KM, Gabbay KH, Quiocho FA: An unlikely sugar substrate site in the 1.65 structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science 1992, 257:81-84.
4. Harrison DH, Bohren KM, Ringe D, Petsko GA, Gabbay KH: An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. Biochemistry 1994, 33:2011-2020.
5. Bohren KM, Grimshaw CE, Lai C-J, Harrison DH, Ringe D, Petsko GA, Gabbay KH: Tyrosine-48 is the proton donor and histidine110 directs substrate selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. Biochemistry 1994, 33:2021-2032.
6. El-Kabbani O, Green NC, Lin GD, Carson M, Narayana SVL, Moore KM, Flynn TG, DeLucas U: Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications. Acta Crystallogr D 1994, 50:859-868.
7. El-Kabbani O, Judge K: Crystallization and preliminary structure of porcine aldehyde reductase-NADPH binary complex. Acta Crystallogr D 1995, 51:605-608.
8. De Winter HL, Von Itzstein M: Aldose reductase as a target for drug design: molecular modeling calculations on the binding of acyclic sugar substrates to the enzyme. Biochemistry 1995, 34:8299-8308.
9. The binding conformations of acyclic carbohydrate substrates of aldose reductase are investigated by molecular modelling techniques on the basis of the X-ray crystal structure of the enzyme. Residues His110, Tyr48 form strong hydrogen bonds with the carbonyl oxygen of the substrate and Trp111 appears to be important in the binding of 2'-hydroxyl-containing substrates. His110 is protonated at Ne2 when an aldehyde substrate is bound, and may serve as a proton donor in the catalytic reaction.
10. De Winter HL, Von Itzstein M: Molecular modelling calculations on the binding of D- and L-xylose to wild-type aldose reductase and its H110Q and H110A mutants. In Enzymology and Molecular Biology of Carbonl Metabolism 5. Edited by Weiner H, Holmes RS, Wermuth B. New York: Plenum Press; 1995:223-229.
11. Ehrig T, Bohren KM, Prendergast FG, Gabbay KH: Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors. Biochemistry 1994, 33:7157-7165.
12. Sarges R, Dates PJ: Aldose reductase inhibitors: recent developments. Prog Drug Res 1993, 40:99-161.
13. Koch K, Biggers MS: General preparation of 7-substituted 4chromanones: synthesis of a potent aldose reductase inhibitor. J Org Chem 1994, 59:1216-1 218.
14. Da Settimo A, Primofiore G, Da Settimo F, Simorini F, La Motta C, Martinelli A, Boldrini E: Synthesis of pyrrolo[3,4-c]pyridine derivatives possessing an acid group and their in vitro and in vivo evaluation as aldose reductase inhibitors. Eur J Med Chem 1996, 31:49-58.
15. Rosen SD, Bertozzi CR: The selectins and their ligands. Curr Opin Cell Biol 1994, 6:663-673.
16. Lasky LA: Selectin-carbohydrate interactions and the initiation of the inflammatory process. Annu Rev Biochem 1995, 64:113-139.
17. This is an excellent review which covers much of the recent literature concerning selectin-carbohydrate interactions, and is a 'must read' for researchers involved in the design and synthesis of selectin inhibitors.
18. Graves BJ, Crowther RL, Chandran C, Rumberger JM, Li S, Huang K-S, Presky DH, Familletti PC, Wolitzky BA, Burns DK: Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains. Nature 1994, 367:532-538.
19. x: potent inhibitors of E-selectinmediated cell adhesion; reagent for staining activated endothelial cells. Glycobiology 1994, 4:259-265.
20. Manning DD, Bertozzi CR, Pohl NL, Rosen SD, Kiessling LL: Selectin-saccharide interactions: revealing structure-function relationships with chemical synthesis. J Org Chem 1995, 60:6254-6255.
21. Bertozzi CR, Fukuda S, Rosen SD: Sulfated disaccharide inhibitors of L-selectin: deriving structural leads from a physiological selectin ligand. Biochemistry 1995, 34:14271-14278.
22. x.
23. Maaheimo H, Renkonen R, Turunen JP, Penttila L, Renkonen O: Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion - evidence that multivalency enhances the saccharide binding to L-selectin. Eur J Biochem 1995, 234:616-625.
24. DeFrees SA, Kosch W, Way W, Paulson JC, Sabesan S, Halcomb RL, Huang D-H, Ichikawa Y, Wong C-H: Ligand recognition by E-selectin: synthesis, inhibitory activity, and conformational analysis of bivalent sialyl Lewis x analogs. J Am Chem Soc 1995, 117:66-79.
25. x derivatives show increased activity against E-selectin and provide useful structure-activity relationships.
26. Huang H, Wong C-H: Synthesis of biologically active sialyl Lewis x mimetics. J Org Chem 1995, 60:3100-3106.
27. Thoma G, Schwarzenbach F, Duthaler RO: Synthesis of a sialyl Lewis x mimic with fixed carboxylic acid group: chemical approach toward the elucidation of the bioactive conformation of sialyl Lewis x. J Org Chem 1996, 61:514-524.
28. Komba S, Ishida H, Kiso M, Hasegawa A: Synthesis of deoxygalactose-containing sialyl Lex ganglioside analogues to elucidate the structure necessary for selectin recognition. Glycoconjugate J 1996, 13:241-254.
29. The synthesis and biological evaluation of some deoxygalactose-containing S-Lex ganglioside analogs are described. Insight into the binding domains of E-, P-, and L-selectin is presented.
30. White CL, Janakiraman MN, Laver WG, Philippen C, Vasella A, Air GM, Luo M: A sialic acid-derived phosphorate analog inhibits different strains of influenza virus neuraminidase with different efficiencies. J Mol S/o/1995, 245:623-634.
31. Singh S, Jedrzejas MJ, Air GM, Luo M, Laver WG, Brouillette WJ: Structure-based inhibitors of influenza virus sialidase. A benzole acid lead with novel interaction. J Med Chem 1995, 38:3217-3225. Noncarbohydrate-based, aromatic inhibitors of influenza-virus sialidase are presented. This class of compound appears to have reasonable in vitro activity against influenza-virus replication and may provide an alternative template for the discovery of potent sialidase inhibitors.
32. Sauter NK, Bednarski MD, Wurzburg BA, Hanson JE, Whitesides GM, Skehel JJ, Wiley DC: Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry 1989, 28:8388-8396.
33. Nagy JO, Wang Peng GJH, Schaefer ME, Hill TG, Callstrom MR, Bednarski MD: Carbohydrate materials bearing neuraminidaseresistant C-glycosides of sialic acid strongly inhibit the in vitro infectivity of influenza virus. J Med Chem 1992, 35:4501-4502.
34. Mammen M, Dahmann G, Whitesides GM: Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. J Med Chem 1995, 38:4179-4190. The synthesis and biological evaluation of polyvalent sialosides is described. A range of C-glycosides of N-acetylneuraminic acid are copolymerized with a polymer that is preactivated by the incorporation of active ester groups. Polyvalency enhances the affinity of influenza virus for haemagglutinin and provides a useful model for the design of inhibitors of other microbe-host interactions.
35. Sigal G, Mammen M, Dahmann G, Whitesides GM: Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: the strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J Am Chem Soc 1996, 118:3789-3800.
36. A Significant Increase in Haemagglutinin Inhibition Is Observed upon Changing from Simple Monovalent Sialosides to Polyvalent Species.
37. Stehle T, Van Y, Benjamin TL, Harrison SC: Structure of murine polyomavirus complexed with an oligosaccharide receptor fragment Nature 1994, 369:160-163.
38. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC: Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988, 333:426-431.
39. Jacob GS: Glycosylation inhibitors in biology and medicine. Curr Opin Struct Biol 1995, 5:605-611.
40. Thunnissen AMWH, Rozeboom HJ, Kalk JH, Dijkstra BW: Structure of the 70 kDa soluble lytic transglycosylase complexed with bulgecin A. Implications for the enzymatic mechanism. Biochemistry 1995, 34:12729-12737.
41. Thunnissen AMWH, Isaacs NW, Kijkstra BW: The catalytic domain of a bacterial lytic transglycosylase defines a novel class of lysozymes. Proteins 1995, 22:245-258.
42. Merritt EA, Hol WGJ: AB5 toxins. Curr Opin Struct Biol 1995, 5:165-171.
43. Sixma TK, Pronk SE, Kalk KH, Van Zanten BAM, Berghuis AM, Hoi WGJ: Lactose binding to heat-labile enterotoxin revealed by X-ray crystallography. Nature 1992, 355:561-564.
44. Merritt EA, Sarfaty S, Van den Akker F, L'hoir C, Martial JA, Hol WGJ: Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sei 1994, 3:166-175.
45. Schön A, Freire E: Thermodynamics of intersubunit interactions in cholera toxin upon binding to the oligosaccharide portion of its cell surface receptor, ganglioside GM1. Biochemistry 1989, 28:5019-5024.
46. Taylor G, Vimr E, Garman E, Laver G: Purification, crystallization and preliminary crystallographic study of neuraminidase from Vibrio cholerae and Salmonella typhimurium LT2. J Mol Biol 1992, 226:1287-1290.
47. Crennell SJ, Garman EF, Laver WG, Vimr ER, Taylor GL: Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase. Proc Natl Acad Sci USA 1993, 90:9852-9856.
48. Crennell S, Garman E, Laver W, Vimr E, Taylor G: Crystal structure of Vibrio cholerae neuraminidase reveals dual lectinlike domains in addition to the catalytic domain. Structure 1994,2:535-544.
49. Gaskell A, Crennell S, Taylor G: The three domains of a bacterial sialidase: α β-propeller, an immunoglobulin module and a galactose-binding jelly-roll. Structure 1995, 3:1197-1205. The X-ray structure of sialidase from Micromonospora virdifaciens is reported. This bacterial sialidase has an additional lectin-like domain, not unlike sialidase from Vibrio cholerae. This combination of an enzyme and lectin domain may be common in bacterial and parasitic sialidases.
50. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK: Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996, 275:295-299. This report details a study of 4-deoxy-4-guanidino-Neu5Ac2en used as an inhibitor in experimental human influenza infection. The data provide support for the effectiveness of the drug candidate for both prevention and early treatment of experimental influenza.